Business Context and Reporting Period
This Form 8-K is a current report filed by RXi Pharmaceuticals Corporation (also referenced as Phio Pharmaceuticals Corp. in metadata) on March 27, 2018. The filing discloses a presentation made by company representatives at the Landmark Venture Forum in Old Greenwich, Connecticut, on the same date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose a conference presentation and does not contain financial statements or operational metrics.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing is limited to the disclosure of a public presentation under Regulation FD.
Guidance, Outlook, and Risks
The company provided a presentation at the Landmark Venture Forum, which is attached as Exhibit 99.1. The filing explicitly states that the information in this Item 7.01 and the attached presentation will not be treated as "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and will not be incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed within the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Conference Presentation) for specific business updates, as the 8-K text only references its existence.
- Verify the company's current name and ticker status, noting the discrepancy between the registrant name "RXi Pharmaceuticals Corporation" and the metadata "Phio Pharmaceuticals Corp."
- Confirm that the presentation content is not legally considered "filed" information under Section 18 of the Exchange Act.
- Check subsequent filings for any financial data or operational updates not included in this disclosure.